<SEC-DOCUMENT>0001104659-17-056738.txt : 20170912
<SEC-HEADER>0001104659-17-056738.hdr.sgml : 20170912
<ACCEPTANCE-DATETIME>20170912160541
ACCESSION NUMBER:		0001104659-17-056738
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170906
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170912
DATE AS OF CHANGE:		20170912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		171081164

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a17-21891_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of report (Date of earliest event reported): <b>September&nbsp;6, 2017</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in its Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-15006&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13-3191702&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other   Jurisdiction&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File   Number)&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of Incorporation)&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification   No.)&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Perryville   III Building, 53 Frontage Road, Suite&nbsp;220,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Hampton,   New Jersey</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">08827</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal   executive offices)&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>(908) 200-7500</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109927\17-21891-1\task8571135\21891-1-ba.htm',USER='109927',CD='Sep 12 19:58 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;5.02&nbsp; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;6, 2017, Thomas Davis, M.D., gave notice of his intention to resign as Executive Vice President and Chief Medical Officer of Celldex Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) to pursue an alternative career path. Dr.&nbsp;Davis&#146;s resignation will be effective as of September&nbsp;29, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;12, 2017, the Company issued a press release announcing the resignation of Dr.&nbsp;Davis. A copy of the press release is furnished as Exhibit&nbsp;99.1 hereto. In accordance with General Instruction B.2 of Form&nbsp;8-K, the information in Item 7.01 of this Current Report on Form&nbsp;8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.&nbsp; Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(d)&nbsp;Exhibits</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a17-21891_1ex99d1.htm#Exhibit99_1_075147" title="Click to goto ">Press   Release, dated September&nbsp;12, 2017.</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_002037_3837"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109927\17-21891-1\task8571135\21891-1-ba.htm',USER='109927',CD='Sep 12 19:58 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Sam Martin</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Sam Martin</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: Senior Vice   President and Chief Financial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated: September&nbsp;12, 2017</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_002111_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109927\17-21891-1\task8571135\21891-1-ba.htm',USER='109927',CD='Sep 12 19:58 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a17-21891_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>







  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1<a name="Exhibit99_1_075147"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="240" height="57" src="g218911mmi001.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Announces Departure of Chief Medical Officer</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">HAMPTON, N.J., September&nbsp;12, 2017 &#151;</font></b> Celldex Therapeutics,&nbsp;Inc. (NASDAQ: CLDX) announced today the resignation of Thomas Davis, M.D., Executive Vice President and Chief Medical Officer of Celldex, effective September&nbsp;29, 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Celldex&#146;s clinical programs have matured greatly during Tom&#146;s tenure. We appreciate his significant contributions and wish him the very best in his future endeavors,&#148; said Anthony Marucci, Co-Founder, President and Chief Executive Officer of Celldex Therapeutics. &#147;We have built an exceptional clinical science team led by four physicians with deep backgrounds in drug development and are confident our clinical programs will meet our planned milestones under their leadership. We look forward to a busy end of year and topline data from the METRIC study, likely in the second quarter of 2018.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Celldex Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward Looking Statement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as &#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; or similar expressions. These forward-looking statements reflect management&#146;s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of glembatumumab vedotin and other Company drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to realize the anticipated benefits from the acquisition of Kolltan and to operate the combined business efficiently; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Fast Track designation for glembatumumab vedotin which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109927\17-21891-1\task8571130\21891-1-mm.htm',USER='109927',CD='Sep 12 19:53 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">all; the failure of the market for the Company&#146;s programs to continue to develop; our ability to protect the Company&#146;s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company&#146;s products; and other factors listed under &#147;Risk Factors&#148; in our annual report on Form&nbsp;10-K and quarterly reports on Form&nbsp;10-Q.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Company Contact</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sarah Cavanaugh<br> Senior Vice President, Corporate Affairs&nbsp;&amp; Administration<br>  </font>Celldex Therapeutics,&nbsp;Inc.<br> (781) 433-3161<br> scavanaugh@celldex.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Charles Liles</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Associate Director,&nbsp;Investor Relations&nbsp;&amp; Corp Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(617) 383-3433</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cliles@celldex.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dan Budwick</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Founder, 1AB Media</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(973) 271-6085</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">dan@1abmedia.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_195332_1111"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109927\17-21891-1\task8571130\21891-1-mm.htm',USER='109927',CD='Sep 12 19:53 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g218911mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g218911mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  Y / # 2(  A$! Q$!_\0
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M>3^IK295=2K ,K#!!&012T5UI6/JX14(J*Z'!ZM\++2:[-YH=Y+I=QG(5,E
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$?D?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
